title: [Not Available].
abstract: Nevirapine, a HIV non nucleosidic reverse transcriptase inhibitor, displays an inter-individual variability in its pharmacokinetics parameters, related to its hepatic metabolism. Based on literature, is the nevirapine therapeutic drug monitoring relevant? In naïve and pre-treated HIV infected patients, the probability of achieving and maintaining an undetectable HIV viral load was significantly associated with a nevirapine plasma trough concentration (Ctrough) >4000 ng/mL. The probability of virologic failure was significantly associated with a Ctrough <3000 ng/mL. Concerning the exposure-toxicity relationship, the emergence of hepatotoxicity was more frequently associated with high Ctrough, especially in case of HCV coinfection. Non-randomized studies have reported the interest of nevirapine therapeutic drug monitoring to optimize the virologic response and, to a lesser extent, to prevent hepatotoxicity. Therefore, the level of evidence of the interest of nevirapine therapeutic drug monitoring is "recommended".
authors.affiliation: UMR 645 - IFR 133, Laboratoire de Pharmacologie Clinique et Toxicologie, CHU Besançon, France. Electronic address: patrice.muret@univ-fcomte.fr.
authors.forename: Patrice
authors.initials: P
authors.lastname: Muret
authors.affiliation: UMR 645 - IFR 133, Laboratoire de Pharmacologie Clinique et Toxicologie, CHU Besançon, France.
authors.forename: Sarah
authors.initials: S
authors.lastname: Piedoux
authors.affiliation: Laboratoire de Pharmacocinétique et Toxicologie, Hôpital de La Timone, Marseille, France.
authors.forename: Caroline
authors.initials: C
authors.lastname: Solas
authors.affiliation: Laboratoire de Pharmacocinétique et Toxicologie, Hôpital de La Timone, Marseille, France.
authors.forename: Sylvie
authors.initials: S
authors.lastname: Quaranta
keywords: level of evidence; nevirapine; niveau de preuve; névirapine; suivi thérapeutique pharmacologique; therapeutic drug monitoring